EGFR突变NSCLC免疫景观特征揭示CD73/腺苷通路为潜在治疗靶点
该研究分析三个肺腺癌切除队列,比较EGFR突变与野生型肿瘤免疫微环境。EGFR突变NSCLC呈免疫惰性表型,CD73/腺苷通路为最上调基因,CD73阻断在免疫健全小鼠模型中显著抑制肿瘤生长。
要点
- EGFR突变NSCLC表现为PD-L1低、TMB低、细胞毒性T细胞减少及TCR克隆性低。
- CD73/腺苷通路(NT5E、ADORA1)在EGFR突变肿瘤中显著上调。
- CD73阻断在免疫健全EGFR突变肺癌小鼠模型中显著抑制肿瘤生长。
核心结论
- EGFR突变NSCLC具有免疫惰性表型,CD73/腺苷通路是潜在治疗靶点。
研究设计与样本
- 分析三个肺腺癌切除队列(TRACERx、 Immune Genomic Profiling of NSCLC及TCGA),比较EGFR突变与野生型肿瘤免疫微环境。
主要发现
- EGFR突变NSCLC表现为PD-L1低、TMB低、细胞毒性T细胞减少及TCR克隆性低,但体外T细胞扩增能力保留。
- 75个免疫检查点基因分析中,EGFR突变肿瘤上调最显著的基因为NT5E和ADORA1,属CD73/腺苷通路。
- 单细胞分析显示肿瘤细胞表达CD73,见于初治和耐药肿瘤。
- 共培养体系中CD73敲低降低调节性T细胞比例。
- 免疫健全EGFR突变肺癌小鼠模型中CD73/腺苷通路显著上调,CD73阻断显著抑制肿瘤生长。
临床怎么用
- EGFR突变NSCLC患者对免疫检查点阻断反应不佳,CD73/腺苷通路阻断可能作为潜在治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Lung adenocarcinomas harboring EGFR mutations do not respond to immune checkpoint blockade therapy and their EGFR wildtype counterpart. The mechanisms underlying this lack of clinical response have been investigated but remain incompletely understood. METHODS: We analyzed three cohorts of resected lung adenocarcinomas (Profiling of Resistance Patterns of Oncogenic Signaling Pathways in Evaluation of Cancer of Thorax, Immune Genomic Profiling of NSCLC, and The Cancer Genome Atlas) and compared tumor immune microenvironment of EGFR-mutant tumors to EGFR wildtype tumors, to identify actionable regulators to target and potentially enhance the treatment response. RESULTS: EGFR-mutant NSCLC exhibited low programmed death-ligand 1, low tumor mutational burden, decreased number of cytotoxic T cells, and low T cell receptor clonality, consistent with an immune-inert phenotype, though T cell expansion ex vivo was preserved. In an analysis of 75 immune checkpoint genes, the top up-regulated genes in the EGFR-mutant tumors (NT5E and ADORA1) belonged to the CD73/adenosine pathway. Single-cell analysis revealed that the tumor cell population expressed CD73, both in the treatment-naive and resistant tumors. Using coculture systems with EGFR-mutant NSCLC cells, T regulatory cell proportion was decreased with CD73 knockdown. In an immune-competent mouse model of EGFR-mutant lung cancer, the CD73/adenosine pathway was markedly up-regulated and CD73 blockade significantly inhibited tumor growth. CONCLUSIONS: Our work revealed that EGFR-mutant NSCLC has an immune-inert phenotype. We identified the CD73/adenosine pathway as a potential therapeutic target for EGFR-mutant NSCLC.
引用
- Le X, Negrao MV, Reuben A, et al. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. J Thorac Oncol. 2020. PMID: 33388477. doi:10.1016/j.jtho.2020.12.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。